Levels of specific glycans significantly distinguish lymph node-positive from lymph node-negative breast cancer patients
Open Access
- 24 June 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 20 (10), 1283-1288
- https://doi.org/10.1093/glycob/cwq090
Abstract
One of the most urgent requirements in breast cancer is the development of a blood-based test for early detection and prognosis. Previously published results found a significant difference between specific glycan levels in patients with advanced breast cancer and healthy controls. The aim of this investigation was to address a more clinically relevant problem, i.e., whether the measurement of specific glycans could identify women with aggressive disease at an early stage. In order to reduce potential bias in this study, blood samples from patients were collected, stored and analyzed in a similar manner. Agalactosyl biantennary glycans (FA2) and glycans containing the sialyl Lewis x epitope (A3F1G1 and A2F1G1) were measured using high throughput normal-phase high-performance liquid chromatography in combination with exoglycosidase digestions in sera from 52 patients with early breast cancer (21 with lymph node-negative and 20 with lymph node-positive disease) and 134 women with benign breast disease. The combined levels of the glycans were significantly higher in patients with lymph node metastases compared to women without these metastases. Lymph node status is the single most important determinant of survival in early stage breast cancer. As high levels of these glycans were associated with nodal metastases, their measurement may provide a new non-invasive approach to determining prognosis in women with newly diagnosed breast cancer.Keywords
This publication has 13 references indexed in Scilit:
- Sweetening the Pot: Adding Glycosylation to the Biomarker Discovery EquationClinical Chemistry, 2010
- Proposal for a standard system for drawing structural diagrams of N‐ and O‐linked carbohydrates and related compoundsProteomics, 2009
- A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progressionGlycobiology, 2008
- Evaluation of the serum N‐linked glycome for the diagnosis of cancer and chronic inflammationProteomics, 2008
- Breast Cancer Diagnosis and Prognosis through Quantitative Measurements of Serum Glycan ProfilesClinical Chemistry, 2008
- A Serum Glycomics Approach to Breast Cancer BiomarkersMolecular & Cellular Proteomics, 2007
- Serum Tumor Markers in Breast Cancer: Are They of Clinical Value?Clinical Chemistry, 2006
- Clinical utility of cytokeratins as tumor markersClinical Biochemistry, 2004
- The discovery, biology, and drug development of sialyl Lea and sialyl LexArchives of Biochemistry and Biophysics, 2004
- Tumor-Associated Carbohydrate AntigensAnnual Review of Immunology, 1984